Wall Street scrambled to figure out the consequences of word from Amgen Inc. and partner UCB SA regarding the 4,100-patient phase III ARCH study with bone-forming agent Evenity (romosozumab) that turned up a surprise safety signal not seen in the previous FRAME experiment in more than 7,000 patients. "Romo nomo?" asked Leerink analyst Geoffrey Porges in a research report.